J Liver Cancer Search

CLOSE


J Liver Cancer > Volume 16(1); 2016 > Article
Journal of Liver Cancer 2016;16(1):57-62.
DOI: https://doi.org/10.17998/jlc.16.1.57    Published online March 31, 2016.
Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib
Dae-ha Kim, Gee ho Min, Dong-won Lee, Ke Ryun Ahn, Ji Hye Kim, Snag-Jun Suh, Young Kul Jung, Hyung Joon Yim
Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
Abstract
Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the vascular endothelial growth factor receptor intracellular kinase pathway and is the first agent to demonstrate a statistically significant improvement in overall survival for patients with advanced hepatocellular carcinoma (HCC). However, there were few cases of partial or complete response reported in the previous studies. We herein report a case of dramatic partial response in a patient who had advanced HCC with multiple lung metastasis and portal vein thrombosis treated with sorafenib.
Key Words: Carcinoma, Hepatocellular; Drug therapy; Sorafenib; Treatment outcome
NULL


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR AUTHORS AND REVIEWERS
Editorial Office
620 Yeoksam Heights Bldg.(FASTFIVE),151 Teheran-ro, Gangnam-gu, Seoul 06132, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2022 by The Korean Liver Cancer Association.

Developed in M2PI

Close layer
prev next